Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome (HST31)Product type:GuidanceProgramme:Highly specialised technologies guidancePublished: 22 May 2024
Digital technologies for delivering multidisciplinary weight-management services: early value assessment (HTE14)Product type:GuidanceProgramme:Health technology evaluationLast updated: 6 March 2024Published: 26 October 2023
Endoscopic sleeve gastroplasty for obesity (IPG783)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 22 February 2024
Semaglutide for managing overweight and obesity (TA875)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 4 September 2023Published: 8 March 2023
Obesity: identification, assessment and management (CG189)Product type:GuidanceProgramme:Clinical guidelineLast updated: 26 July 2023Published: 27 November 2014
Semaglutide for managing overweight and obesity in young people aged 12 to 17 years (terminated appraisal) (TA910)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 13 July 2023
Setmelanotide for treating obesity caused by LEPR or POMC deficiency (HST21)Product type:GuidanceProgramme:Highly specialised technologies guidancePublished: 6 July 2022
Liraglutide for managing overweight and obesity (TA664)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 9 December 2020
Naltrexone–bupropion for managing overweight and obesity (TA494)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 12 December 2017
Obesity: working with local communities (PH42)Product type:GuidanceProgramme:Public health guidelineLast updated: 5 June 2017Published: 28 November 2012
Single-anastomosis duodeno-ileal bypass with sleeve gastrectomy for treating morbid obesity (IPG569)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 23 November 2016
Obesity prevention (CG43)Product type:GuidanceProgramme:Clinical guidelineLast updated: 13 March 2015Published: 13 December 2006
Preventing excess weight gain (NG7)Product type:GuidanceProgramme:NICE guidelinePublished: 13 March 2015
Weight management: lifestyle services for overweight or obese adults (PH53)Product type:GuidanceProgramme:Public health guidelinePublished: 28 May 2014
Implantation of a duodenal–jejunal bypass sleeve for managing obesity (IPG471)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 27 November 2013
Weight management: lifestyle services for overweight or obese children and young people (PH47)Product type:GuidanceProgramme:Public health guidelinePublished: 23 October 2013
Laparoscopic gastric plication for the treatment of severe obesity (IPG432)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 27 November 2012
Obesity: clinical assessment and management (QS127)Product type:Quality standardPublished: 4 August 2016
Obesity in adults: prevention and lifestyle weight management programmes (QS111)Product type:Quality standardPublished: 19 January 2016
Obesity in children and young people: prevention and lifestyle weight management programmes (QS94)Product type:Quality standardPublished: 23 July 2015
Tirzepatide for managing overweight and obesity [ID6179]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 14 January 2025
Overweight and obesity managementStatus:In developmentProgramme:NICE guidelineExpected publication date: TBC
Oral semaglutide for managing overweight and obesity [ID6188]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Semaglutide for treating obesity-related heart failure with preserved ejection fraction TS ID 11788Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Setmelanotide for treating obesity caused by a rare genetic disorder in children aged 2 to 5 TS ID 11827Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Obesity: clinical assessment and management (QS update)Status:In developmentExpected publication date: TBC
Obesity: prevention and lifestyle management (QS update)Status:In developmentExpected publication date: TBC
Setmelanotide for treating acquired hypothalamic obesity in people 4 years and older TSID 11995Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Semaglutide for preventing major cardiovascular events in people with cardiovascular disease and living with overweight or obesity ID6441Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Orforglipron for managing overweight and obesity TS ID 12102Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC